12.37
+9.57%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ginkgo Bioworks Holdings
From its filings with the US Securities and Exchange Commission
Ginkgo Bioworks Holdings is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on NYSE under the ticker DNA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $170.2m and a net loss of $312.8m. At that date it held total assets of $1.12bn and shareholders' equity of $508.6m. By business, Cell Engineering brought in 78.0% of revenue, followed by Service at 22.0%.
Our mission is to make biology easier to engineer. That has never changed. Every choice we’ve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.
2.Biology matters. The ability to engineer biology has had and will have a profound impact on how we develop new medicines and vaccines, grow our food, and manufacture many of the things we use every day.
3.Biology is hard. Today, it is still too difficult and too costly to engineer biology, preventing critical innovations from reaching the market.
Ginkgo sells services to government and commercial customers in two business segments: cell engineering, where we provide tools and biological R&D services across a range of industries, and biosecurity, where we provide services to customers who are working to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. An overview of these two business segments is provided below.
Because engineering biology is difficult and unpredictable, biotech R&D is traditionally performed by in-house labs filled with highly trained scientists running lab experiments by hand over several years in the hope of ultimately developing a working product. Many cell engineering projects fail in development due to scientific challenges, and many are terminated because they are taking too long or are over budget.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 19 Apr 2021
- Employees
- 485
- Website
- investors.ginkgobioworks.com ↗
- Head office
- 27 DRYDOCK AVENUE, BOSTON, MA, 02210
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Shyam SankarIndependent Chairman of the Board$508,747
- Dr. Reshma ShettyPresident, Chief Operating Officer, Director, since 2021$1.2m
- Dr. Jason KellyChief Executive Officer, Director, since 2021$1.2m
- Mr. Steven CoenChief Financial Officer, since 2025
- Mr. Ross FubiniIndependent Director$830,550
- Dr. Kathy HannanIndependent Director$467,884
- Mr. Christian HenryIndependent Director$477,500
- Dr. Sri KosuriIndependent Director$807,458
- Mr. Harry SloanIndependent Director$460,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 3
- Social
- 89
- Governance
- 56
- Direct emissions (scope 1)
- 1,060.819 t
- Energy emissions (scope 2)
- 2,254.255 t
- Women in the workforce
- 41.4%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ginkgo Bioworks has 1,292 full-time employees in Boston, Massachusetts.
- The Foundry segment offers R&D services for cell programming platform collaborations.
- Biosecurity segment provides COVID-19 testing to public health authorities.
Weaknesses
- Ginkgo Bioworks has 485 employees in the Materials sector.
- The company's IPO was on 19 April 2021.
- Cell programming platform assets include robotics and data analytics.
Opportunities
- Ginkgo Bioworks' cell programs produce therapeutics and food ingredients.
- The Foundry segment collaborates with partners for cell programming platform services.
- Biosecurity segment expands with adeno-associated virus capsid platform.
Threats
- Ginkgo Bioworks operates in the Chemicals industry with Materials sector.
- The company faces competition in the biotech sector.
- Cell programming platform requires significant investment in robotics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.